Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: A Danish nationwide cohort study

Journal of Internal Medicine

Volumn 277, Issue 4, 2015, Pages 447-455

  Ahlehoff, O ^a,b   Gislason, G ^b,c   Lamberts, M ^b   Folke, F ^d   Lindhardsen, J ^b,d   Larsen, C T ^a   Torp Pedersen, C ^e   Hansen, P R ^b  

^a Mental Health Center Glostrup   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d University of Copenhagen   (Denmark)

^e AALBORG UNIVERSITY   (Denmark)

Author keywords

Atrial fibrillation; CHA2DS2VASc; Inflammation; Psoriasis; Stroke

Indexed keywords

ANTIPSORIASIS AGENT; CYCLOSPORIN; METHOTREXATE; PSORALEN; RETINOID; TUMOR NECROSIS FACTOR INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CEREBROVASCULAR ACCIDENT; CHA2DS2VASC SCORE; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NONVALVULAR ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PUVA; SENSITIVITY ANALYSIS; THROMBOEMBOLISM; ATRIAL FIBRILLATION; DENMARK; INCIDENCE; MIDDLE AGED; MORTALITY; RISK ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COHORT STUDIES; DENMARK; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PSORIASIS; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

EID: 84925368431     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12272     Document Type: Article

References (36)

1. Tsang TS, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis 2005; 48: 1-8.
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
3. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. J Am Acad Dermatol 2010; 62: 621-6.
4. Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol 2008; 88: 337-40.
5. Berrettini M, Parise P, Constantini V, Grasselli S, Nenci GG. Platelet activation in psoriasis. Thromb Haemost 1985; 53: 195-7.
6. Kaplan MJ. Management of cardiovascular disease risk in chronic inflammatory disorders. Nat Rev Rheumatol 2009; 5: 208-17.
7. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2013; 2: e000062.
8. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340-6.
9. Ahlehoff O, Gislason GH, Lindhardsen J et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One 2011; 6: e18125.
10. Ahlehoff O, Gislason GH, Jorgensen CH et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012; 33: 2054-64.
11. Ahlehoff O, Gislason GH, Charlot M et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-57.
12. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47.
13. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
14. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.
15. Frost L, Vukelic Andersen L, Vestergaard P, Husted S, Mortensen LS. Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation: National Cohort Study in Denmark, 1980-2002. Neuroepidemiology 2006; 26: 212-9.
16. Olesen JB, Lip GY, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124.
17. Kumler T, Gislason GH, Kirk V et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 2008; 10: 658-60.
18. Ekholm O, Hesse U, Davidsen M, Kjoller M. The study design and characteristics of the Danish national health interview surveys. Scand J Public Health 2009; 37: 758-65.
19. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007; 28: 150-4.
20. Gelfand JM, Dommasch ED, Shin DB et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411-8.
21. Lindhardsen J, Ahlehoff O, Gislason GH et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012; 344: e1257.
22. Torres T, Sales R, Vasconcelos C, Martins daSilva B, Selores M. Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol 2013; 40: 923-6.
23. Eder L, Chandran V, Gladman DD. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 2013. doi: 10.1136/annrheumdis-2013-203433. [Epub ahead of print].
24. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
25. Solomon DH, Kremer J, Curtis JR et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69: 1920-5.
26. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
27. Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009; 161: 1-7.
28. Balci DD, Balci A, Karazincir S et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 1-6.
29. Semb AG, Rollefstad S, Provan SA et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 2013; 40: 359-68.
30. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-6.
31. Kimball AB, Guerin A, Latremouille-Viau D et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 2010; 123: 350-7.
32. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
33. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012; 60: 2263-70.
34. Pinto A, Tuttolomondo A, Casuccio A et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) 2009; 116: 781-9.
35. Projahn D, Koenen RR. Platelets: key players in vascular inflammation. J Leukoc Biol 2012; 92: 1167-75.
36. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012 2012; 33: 1635-701.